Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyGynecological OncologyThoracic TumorsTumor, regardless of entityDiseaseBreast CancerLung Carcinoma, Non-Small CellLung Carcinoma, Small CellThyroid CancerTumor, Various OrgansTumor Biomarker DefinedSubgroupRET fusion positiveICD10C34.-C50.-C73MeSHBreast NeoplasmsCarcinoma, Non-Small-Cell LungNeoplasmsSmall Cell Lung CarcinomaThyroid NeoplasmsSequenceChemotherapyChemo-substanceCisplatinHydrocortisoneSelpercatinibThiotepaChemo-substanceCisplatinHydrocortisoneSelpercatinibThiotepaChemo-substanceCisplatinHydrocortisoneSelpercatinibThiotepaChemo-substanceCisplatinHydrocortisoneSelpercatinibThiotepaNo. Substances12 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksCardiotoxicityConstipationDiarrheaEmetogenicityHepatotoxicityHypertensionPyrexiaQTc Time ExtensionRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorDrilon AMaisch BMartinoni A DiseaseMaligner Perikarderguss, hämodynamisch relevantRET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2OriginCardiology Unit, Milan, ItalyDepartment of Internal Medicine-Cardiology, Philipps University, Marburg, GermanyMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Protocols in Revision 3 protocols foundProtocols under revision.Cisplatin 30, Tumor, Various Organs (PID2371)Selpercatinib 160, Tumor Biomarker Defined (PID1732)Thiotepa 15 / Hydrocortisone 30, Tumor, Various Organs (PID2372)
